Treatment of Autoimmune Diabetes by Inhibiting the Initial Event
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recent papers have shown that the initial event in the pathogenesis of autoimmune type 1 diabetes (T1D) comprises sensing of molecular patterns released from apoptotic β-cells by innate immune receptors such as toll-like receptor (TLR). We have reported that apoptotic β-cells undergoing secondary necrosis called ‘late apoptotic’ β-cells stimulate dendritic cells (DCs) and induce diabetogenic T cell priming through TLR2. The role of other innate immune receptors such as TLR7 or TLR9 in the initiation of T1D has also been suggested. We hypothesized that TLR2 blockade could inhibit T1D at the initial step of T1D. Indeed, when a TLR2 agonist, Pam3CSK4 was administered chronically, the development of T1D in nonobese diabetic (NOD) mice was inhibited. Diabetogenic T cell priming by DCs was attenuated by chronic treatment with Pam3CSK4, indicating DC tolerance. For the treatment of established T1D, immune tolerance alone is not enough because β-cell mass is critically reduced. We employed TLR2 tolerance in conjunction with islet transplantation, which led to reversal of newly established T1D. Dipeptidyl peptidase 4 (DPP4) inhibitors are a new class of anti-diabetic agents that have beneficial effects on β-cells. We investigated whether a combination of DPP4 inhibition and TLR2 tolerization could reverse newly established T1D without islet transplantation. We could achieve normoglycemia by TLR2 tolerization in combination with DPP4 inhibition but not by TLR2 tolerization or DPP4 inhibition alone. β-cell mass was significantly increased by combined treatment with TLR2 tolerization and DPP4 inhibition. These results suggest the possibility that a novel strategy of TLR tolerization will be available for the inhibition or treatment of established T1D when combined with measures increasing critically reduced β-cell mass of T1D patients such as DPP4 inhibition or stem cell technology.
Abstract
Recent papers have shown that the initial event in the pathogenesis of autoimmune type 1 diabetes (T1D) comprises sensing of molecular patterns released from apoptotic β-cells by innate immune receptors such as toll-like receptor (TLR). We have reported that apoptotic β-cells undergoing secondary necrosis called ‘late apoptotic’ β-cells stimulate dendritic cells (DCs) and induce diabetogenic T cell priming through TLR2. The role of other innate immune receptors such as TLR7 or TLR9 in the initiation of T1D has also been suggested. We hypothesized that TLR2 blockade could inhibit T1D at the initial step of T1D. Indeed, when a TLR2 agonist, Pam3CSK4 was administered chronically, the development of T1D in nonobese diabetic (NOD) mice was inhibited. Diabetogenic T cell priming by DCs was attenuated by chronic treatment with Pam3CSK4, indicating DC tolerance. For the treatment of established T1D, immune tolerance alone is not enough because β-cell mass is critically reduced. We employed TLR2 tolerance in conjunction with islet transplantation, which led to reversal of newly established T1D. Dipeptidyl peptidase 4 (DPP4) inhibitors are a new class of anti-diabetic agents that have beneficial effects on β-cells. We investigated whether a combination of DPP4 inhibition and TLR2 tolerization could reverse newly established T1D without islet transplantation. We could achieve normoglycemia by TLR2 tolerization in combination with DPP4 inhibition but not by TLR2 tolerization or DPP4 inhibition alone. β-cell mass was significantly increased by combined treatment with TLR2 tolerization and DPP4 inhibition. These results suggest the possibility that a novel strategy of TLR tolerization will be available for the inhibition or treatment of established T1D when combined with measures increasing critically reduced β-cell mass of T1D patients such as DPP4 inhibition or stem cell technology.
참고문헌 (16)
- Kim, Y. -H., "Apoptosis of pancreatic β-cells detected in accelerated diabetes of NOD mice:no role of Fas-Fas ligand interaction in autoimmune diabetes", Eur. J. Immunol, 29, pp.455~465 (1999)
- O’Brien, B. A., "Apoptosis is the mode of β-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse", Diabetes, 46, pp.750~757 (1997)
- Finegood, D. T., "β-cell mass dynamics in Zucker Diabetic Fatty rats", Diabetes, 50, pp.1021~1029 (2001)
- Trudeau, J. D., "Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes?", Diabetes, 49, pp.1~7 (2000)
- Kim, H. S., "Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes", Immunity, 27, pp.321~333 (2007)
- Diana, J., "Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes", Nat. Med, 19, pp.65~73 (2013)
- Cavaillon, J. M., "Endotoxin tolerance: is there a clinical relevance?", J. Endotoxin Res, 9, pp.101~107 (2003)
- Kim, D. H., "Inhibition of autoimmune diabetes by TLR2 tolerance", J. Immunol, 187, pp.5211~5220 (2011)
- Xiong, Y., "IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance", J. Leukocyte Biol, 94, pp.291~300 (2013)
- Mu, J., "Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes", Diabetes, 55, pp.1695~1704 (2006)
- Xu, G., "Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats", Diabetes, 48, pp.2270~2276 (1999)
- Butler, A. E., "Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors", Diabetes, 62, pp.2595~2604 (2013)
- Cho, J. M., "A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis", Diabetes Res. Clin. Pract, 91, pp.72~79 (2011)
- Kim, D. H., "Treatment of autoimmune diabetes by toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition", Diabetologia, 55, pp.3308~3317 (2012)
- Jeon, K., "Differentiation and Transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model", Stem Cells Dev, 21, pp.2642~2655 (2012)
- Turley, S., "Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model", J. Exp. Med, 198, pp.1527~1537 (2003)